What is ANI Pharmaceuticals's accrued licensor payment?

ANI Pharmaceuticals (ANIP) reported accrued licensor payment of $0 in Q1 2026.

How has ANI Pharmaceuticals's accrued licensor payment changed year-over-year?

ANI Pharmaceuticals's accrued licensor payment decreased by 100.0% year-over-year, from $11.07M to $0.

ANI Pharmaceuticals ANIP Accrued licensor payment

Other financials

Income statement

See full

Revenue$237.5M+20.5%

Gross profit$143.9M+16.0%

Operating income$38.9M+48.5%

Net income$29.5M+88.1%

EPS (diluted)$1.28+85.5%

Balance sheet

See full

Cash & equivalents$311.2M+108%

Total debt$305.3M-3.5%

Total equity$562.3M+34.3%

Total assets$1.4B+10.0%

Cash flow

See full

Operating cash flow$58.4M+66.8%

CapEx$6.1M+146%

Free cash flow$52.3M+60.8%

Valuation

See full

Market cap$1.88B+18.3%

Enterprise value$1.87B+5.8%

P/E20.4×—

P/S2×-0.3×

Profitability

See full

Gross margin60.8%+1.5pp

Operating margin13.4%—

Net margin10%+8.1pp

FCF margin20.7%+10.8pp

Returns & leverage

See full

Return on equity18.8%+15.6pp

Debt / equity0.5×-0.2×

Current ratio3.1×+0.5×

Where this comes from

Reported directly by ANI Pharmaceuticals in its filing.

Tagged under the XBRL concept anip:AccruedLicensorPaymentsNoncurrentFairValueDisclosure.

The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about ANI Pharmaceuticals's accrued licensor payment.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ANI Pharmaceuticals's accrued licensor payment?: ANI Pharmaceuticals (ANIP) reported accrued licensor payment of $0 in Q1 2026.
How has ANI Pharmaceuticals's accrued licensor payment changed year-over-year?: ANI Pharmaceuticals's accrued licensor payment decreased by 100.0% year-over-year, from $11.07M to $0.